Evidence item

The quoted passage directly reports a 95% disease-control rate and identifies 40 participants, but it does not itself state the 2026 date, phase 1b/2 design, untreated status, HER2-positive status, or advanced biliary-tract-cancer population. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 24738

Source: Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial · locator {} · excerpt hash sha256:3bb41b5b0e9b2ae91874b4ad7576efb2c763ff5ef684f081746f6686e5eedb1e

Here the primary endpoint was met with an objective response rate of 55% (95% confidence interval (CI) 38.5–70.7; one complete response and 21 partial responses among 40 participants) and a disease control rate of 95% (95% CI 83.5–99.4); the median duration of response was 12.6 months (95% CI 5.7–not reached).